Reset filter
Palabras clave
Multiple Sclerosis, Acute Relapsing ×
Mostrar más Palabras clave
Tabla de contenido
  1. 1. Ensayo clínico
  2. 2. Documentación de rutina
  3. 3. Estudio de registro / cohorte
  4. 4. Seguro de calidad
  5. 5. Estándar de datos
  6. 6. Resultado reportado por el paciente
  7. 7. Especialidad médica
    1. 7.1. Anestesiología
    1. 7.2. Dermatología
    1. 7.3. ENT
    1. 7.4. Geriatría
    1. 7.5. Ginecología / Obstetricia
    1. 7.6. Medicina Interna
      1. Hematología
      1. Enfermedades infecciosas
      1. Cardiología / Angiología
      1. Neumología
      1. Gastroenterología
      1. Nefrología
      1. Endocrinología / Enfermedades metabólicas
      1. Reumatología
    1. 7.7. Neurología
    1. 7.8. Oftalmología
    1. 7.9. Cuidados paliativos
    1. 7.10. Patología / Forense
    1. 7.11. Pediatría
    1. 7.12. Psiquiatría / Psicosomática
    1. 7.13. Radiología
    1. 7.14. Cirugía
      1. Cirugía General / Visceral
      1. Neurocirugía
      1. Cirugía plástica
      1. Cirugía Torácica
      1. Traumatología / Ortopedia
      1. Cirugía vascular
    1. 7.15. Urología
    1. 7.16. Odontología / OMS
Modelos de datos seleccionados

Debe iniciar sesión para seleccionar modelos de datos para descargar o realizar un análisis.

110 Resultados de la búsqueda.
Relevancia Evaluación Nuevo primero Antiguo primero

Screening: MRI Multiple Sclerosis ALAIN01 NCT02419378

- 3/6/16 - 1 formulario, 1 itemgroup, 16 items, 1 idioma
Itemgroup: MRI
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Part: Screening

NINDS CDERelapse Multiple Sclerosis - Relapse

- 28/6/16 - 1 formulario, 1 itemgroup, 23 items, 1 idioma
Itemgroup: Relapse
NINDS Common Data Elements, Multiple Sclerosis Relapse Used from the National Institute of Neurological Disorders and Stroke Common Data Elements (https://www.commondataelements.ninds.nih.gov/) References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen J, Kunitz S. National Institute of Neurological Disorders and Stroke Common Data Element Project - approach and methods. Clin Trials. 2012;9(3):322-9.

Screenning: EDSS Multiple Sclerosis ALAIN01 NCT02419378

- 31/5/16 - 1 formulario, 1 itemgroup, 12 items, 1 idioma
Itemgroup: EDSS
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Part: Screenning

Eligibility Relapsing-Remitting Multiple Sclerosis NCT02428218

- 30/6/19 - 1 formulario, 1 itemgroup, 11 items, 1 idioma
Itemgroup: Criteria
Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS); ODM derived from: https://clinicaltrials.gov/show/NCT02428218

Eligibility NCT00078338 Multiple Sclerosis - Eligibility

- 20/9/21 - 1 formulario, 3 itemgroups, 34 items, 2 idiomas
Itemgroups: Inclusion criteria, Exclusion criteria, Medical Concepts
Rebif(R) Versus Copaxone(R) in the Treatment of Relapsing Remitting Multiple Sclerosis Inclusion Criteria: - Be between 18 and 60 years of age - Have definite relapsing multiple sclerosis - Have had one or more relapses within the prior 12 months - Must be in a clinically stable or improving neurological state during the four weeks prior to Study Day 1 - EDSS score from 0 to 5.5, inclusive - If female, she must either be post-menopausal or surgically sterilized; or use a hormonal contraceptive, intra uterine device, diaphragm with spermicide, or condom with spermicide, for the duration of the study; and be neither pregnant nor breast-feeding - Confirmation that the subject is not pregnant must be established by a negative serum hCG pregnancy test within 7 days of Study Day 1 and a negative urine pregnancy test on Study Day 1. A pregnancy test is not required if the subject is post-menopausal or surgically sterilized - Be willing and able to comply with the protocol for the duration of the study - Voluntarily provide written informed consent and, for USA sites only, a subject authorization under Health Insurance Portability and Accountability Act (HIPAA), prior to any study-related procedure that is not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to their future medical care. Exclusion Criteria: - Have secondary progressive MS or primary progressive MS - Prior use of any interferon or glatiramer acetate - Have had treatment with oral or systemic corticosteroids or ACTH within 4 weeks of Study Day 1 and within 7 days prior to the Day 1 MRI. - Have a psychiatric disorder that is unstable or would preclude safe participation in the study - Have significant leukopenia (white blood cell count < 0.5 times the lower limit of normal of the central laboratory) within 7 days of Study Day 1 - Have elevated liver function tests (AST, ALT, alkaline phosphatase > 2.0 times the upper limit of normal (ULN) of the central laboratory, or total bilirubin > 1.5 times the ULN of the central laboratory) within 7 days of Study Day 1 or a history of hepatitis (including infectious or drug-induced) - Prior cytokine or anti-cytokine therapy within 3 months prior to Study Day 1 - Prior use of immunomodulatory or immunosuppressive therapy (including but not limited to cyclophosphamide, cyclosporin, methotrexate, azathioprine, linomide, mitoxantrone) within the 12 months prior to Study Day 1 - Prior use of cladribine or have received total lymphoid irradiation - Have allergy or hypersensitivity to human serum albumin, mannitol, glatiramer acetate, natural or recombinant interferon-β, or any other components of the study drugs or gadolinium DTPA - Have taken intravenous immunoglobulin or any other investigational drug or taken part in any experimental procedure in the 6 months prior to Study Day 1 - Presence of systemic disease that might interfere with subject safety, compliance or evaluation of the condition under study (e.g. insulin-dependent diabetes, Lyme disease, clinically significant cardiac disease, HIV, HTLV-1) - Have had plasma exchange in 3 months prior to Study Day 1

Eligibility Relapsing Multiple Sclerosis NCT00472797

- 17/9/21 - 1 formulario, 2 itemgroups, 23 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
Rebif New Formulation (RNF) Quality of Life (QOL) Study; ODM derived from: https://clinicaltrials.gov/show/NCT00472797

MSFC Multiple Sclerosis ALAIN01 NCT02419378

- 28/5/16 - 1 formulario, 4 itemgroups, 28 items, 1 idioma
Itemgroups: MSFC, Timed 25-Foot Walk, 9-Hole Peg Test, PASAT
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany

Eligibility NCT01081782 Multiple Sclerosis - Eligibility

- 17/9/21 - 1 formulario, 2 itemgroups, 8 items, 2 idiomas
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT01081782

Eligibility Multiple Sclerosis NCT00011375

- 17/9/21 - 1 formulario, 2 itemgroups, 21 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
Rolipram to Treat Multiple Sclerosis; ODM derived from: https://clinicaltrials.gov/show/NCT00011375

MS Diagnostic Criteria CRFs Multiple Sclerosis Tysabri NCT00027300

- 30/1/17 - 1 formulario, 1 itemgroup, 4 items, 1 idioma
Itemgroup: MS Diagnostic Criteria
The purpose of this study is to determine the safety and efficacy of natalizumab in the treatment of individuals who have been diagnosed with relapsing remitting multiple sclerosis (MS). It is hoped that natalizumab will prevent certain types of white blood cells from moving out of the bloodstream into organs, including the brain, that are being damaged by autoimmune disease (a disease in which the body's own immune system attacks certain organs). These white blood cells are thought to cause inflammation that can result in lesions (small areas of damage) in the brain. These lesions are thought to be the cause of relapses and disability in MS. Documentation process: This form is to be obtained in Screening.

Eligibility Relapsing- Remitting Multiple Sclerosis NCT01842191

- 20/9/21 - 1 formulario, 2 itemgroups, 10 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
Efficacy of Fish Oil in Multiple Sclerosis; ODM derived from: https://clinicaltrials.gov/show/NCT01842191

Eligibility Multiple Sclerosis, Relapsing-remitting NCT01080001

- 20/9/21 - 1 formulario, 2 itemgroups, 12 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Observational, Prospective Study to Assess the Impact of Fatigue in the Quality of Life of Patients With Multiple Sclerosis in Argentina; ODM derived from: https://clinicaltrials.gov/show/NCT01080001

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial